Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
20.7M
-
Shares change
-
-1.51M
-
Total reported value, excl. options
-
$544M
-
Value change
-
-$29.7M
-
Put/Call ratio
-
1.49
-
Number of buys
-
47
-
Number of sells
-
-60
-
Price
-
$26.20
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q4 2017
156 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q4 2017.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.7M shares
of 27.8M outstanding shares and own 74.65% of the company stock.
Largest 10 shareholders include Birchview Capital, LP (2.18M shares), CREDIT SUISSE AG/ (2.14M shares), BlackRock Inc. (1.68M shares), Vanguard Group Inc (1.33M shares), CANNELL PETER B & CO INC (1.12M shares), BLAIR WILLIAM & CO/IL (1.02M shares), ArrowMark Colorado Holdings LLC (934K shares), NEXT CENTURY GROWTH INVESTORS LLC (660K shares), Nuveen Asset Management, LLC (654K shares), and LOOMIS SAYLES & CO L P (632K shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.